Recursion Pharmaceuticals, Inc. Stock price

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
9.97 USD -1.97% Intraday chart for Recursion Pharmaceuticals, Inc. -9.94% +1.12%
Sales 2024 * 53.92M Sales 2025 * 60.67M Capitalization 2.39B
Net income 2024 * -411M Net income 2025 * -481M EV / Sales 2024 * 38.4 x
Net cash position 2024 * 322M Net cash position 2025 * 279M EV / Sales 2025 * 34.8 x
P/E ratio 2024 *
-5.99 x
P/E ratio 2025 *
-5.42 x
Employees 500
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.45%
1 week-8.13%
Current month-24.44%
1 month-34.47%
3 months-4.95%
6 months+30.72%
Current year+3.14%
More quotes
1 week
10.07
Extreme 10.0701
10.91
1 month
10.07
Extreme 10.0701
14.12
Current year
8.68
Extreme 8.675
15.74
1 year
4.54
Extreme 4.54
16.75
3 years
4.54
Extreme 4.54
42.81
5 years
4.54
Extreme 4.54
42.81
10 years
4.54
Extreme 4.54
42.81
More quotes
Managers TitleAgeSince
Founder 41 13-11-04
Founder 42 13-11-04
Founder 62 13-11-04
Members of the board TitleAgeSince
Director/Board Member 61 20-03-19
Chairman 60 20-03-31
Founder 62 13-11-04
More insiders
Date Price Change Volume
24-03-28 9.97 -1.97% 5 433 595
24-03-27 10.17 -1.45% 3,999,372
24-03-26 10.32 -1.99% 5,067,181
24-03-25 10.53 +0.38% 3,831,136
24-03-22 10.49 -1.50% 3,695,419

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company's platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. It integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.17 USD
Average target price
13 USD
Spread / Average Target
+27.83%
Consensus
  1. Stock
  2. Equities
  3. Stock Recursion Pharmaceuticals, Inc. - Nasdaq